Epitalon
Epitalon
Epitalon is a longevity peptide associated with telomere narratives, but that popularity has not translated into legal compounding support.
Current status
Restricted
Longevity-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Would likely need broader peptide policy reform to move meaningfully.
Primary Use
Longevity-related interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 29, 2023
Current status signal recorded: Current federal posture remains restrictive..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Epitalon status changes
State-specific notes
New York
Long-shot sourcing despite market demand.